RetinAI and Geographic Atrophy (GA) Expert Working Group partner to enable data collaboration and automated analysis of GA biomarkers for CAM using Discovery

Bern, Switzerland and Boston, U.S.A, April 17 2023

RetinAI Medical AG (“RetinAI”), a leader in the management and analysis of healthcare data through AI, partnered with the Classification of Atrophy Meeting (CAM) Group in December 2022 to provide RetinAI’s Discovery® platform to the expert working group, consisting of more than 30 members, to facilitate peer-to-peer data collaboration and perform accelerated, automated biomarker analysis of real-world datasets of geographic atrophy (GA) patients. 

‍

RetinAI’s Discovery and its models for GA segmentation and atrophy prediction were featured at the CAM 8 meeting that took place from February 3-5th, 2023. The platform continues to serve the CAM group for providing a detailed look at imaging biomarkers across longitudinal datasets of GA with multi-modal OCT and FAF imaging.

‍

RetinAI is excited to have its Discovery platform and its AI used within the CAM group as an integral part of analyzing data for identification of biomarkers in GA. The company’s advanced technology platform enables the expert group to work collaboratively, leading to more effective consensus on new biomarkers, in addition to efficiently analyzing large-scale datasets through the use of AI for biomarker discovery and validation. 

‍

Discovery will be used at the upcoming CAM 9 scientific meeting in Baden Baden, Germany, September 7-9th, 2023 to help organize real-world datasets and facilitate the group’s analysis of key research questions resulting from discussions and analysis at CAM 8. “We designed Discovery to accelerate and enhance healthcare collaboration and analysis through developing advanced technology for data management and AI for Ophthalmology data. We are pleased to support CAM’s ongoing analysis efforts for their objectives to refine definitions in GA and we look forward to being a part of the CAM 9 meeting” says Sandro De Zanet, PhD, Chief Scientific Officer of RetinAI.

‍

About RetinAI

RetinAI Medical AG (RetinAI), founded in early 2017, is a Swiss company developing software solutions to accelerate clinical, research and pharmaceutical workflows globally using advanced machine learning and computer vision. RetinAI builds tools to collect, organize and analyze health data from the eyes, enabling healthcare professionals to make the right decisions sooner in healthcare. RetinAI's international team leverages its clinical, technical, and scientific expertise to foster the transition from reactive to preventive medicine for severe eye diseases. www.retinai.com

‍